News

Dr Schnipper brings with him 20 years of experience in the clinical development of medicines for the pharmaceutical and biotechnology industries. He also took up responsibility for many

GW Pharma and Otsuka signed the agreement in July 2007 with a three year term, and the collaboration is now extended upto the end of June 2013. As

TG 101348, an oral agent, is a potent inhibitor of Janus kinase 2 (JAK-2), developed for the treatment of patients with myeloproliferative diseases including myelofibrosis (MF). TargeGen said

Teva Pharmaceutical Industries currently has Rx approval for these products, and Teva and Sanofi-Aventis have settled their Paragraph IV/Hatch-Waxman litigation. Allegra 180mg, 60mg, and Allegra D-12 are indicated

On June 1, 2010, AMAG had submitted MAA for Feraheme for the treatment of iron deficiency anemia (IDA) in chronic kidney disease patients. AMAG has two partners for

The new laboratory is expected to deliver site support services to clinical investigators throughout China and offers overall benefits including shorter shipping distances between clinical sites and existing

As per the agreement, OctoPlus is expected to develop, making use of its PolyActive technology, in-vivo feasibility, a controlled release formulation of an undisclosed compound. Novartis is expected

Claros has been preparing its urology product for the European launch and continuing the process to attain regulatory clearance in other markets, including the US. The approval follows

Ganeden Biotech and Glanbia Nutritionals are expected to provide a stick pack containing an immune health micronutrient premix from Glanbia Nutritionals and GanedenBC30. GanedenBC30 is a probiotic that